New cancer pill enters first human tests for advanced solid tumors

NCT ID NCT06328439

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early-phase trial is testing an experimental oral drug called ANS014004 in 40 adults with advanced solid tumors that have not responded to standard treatments. The study has two parts: first, finding the safest dose, then expanding to see if the drug can shrink tumors. The main focus is on safety and side effects, with tumor response measured every 8 weeks.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
ANS014004 (an oral drug)
What this could lead to
If this drug is safe and shows signs of shrinking tumors, it could lead to a new treatment option for people with advanced solid cancers that have stopped responding to standard therapies.
What could go wrong
This is a very early Phase 1 trial with only 40 participants, so the main goal is safety, not effectiveness. The drug may not work or could cause side effects, and it will take years of further testing before it might become available.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for LOCALLY ADVANCED OR METASTATIC SOLID TUMORS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Shanghai Chest Hospital

    Shanghai, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.